Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
51,252,511
-
Total 13F shares
-
4,357,920
-
Share change
-
-762,217
-
Total reported value
-
$8,168,237
-
Put/Call ratio
-
67%
-
Price per share
-
$1.88
-
Number of holders
-
30
-
Value change
-
-$1,261,029
-
Number of buys
-
7
-
Number of sells
-
9
Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q4 2023
As of 31 Dec 2023,
Protara Therapeutics, Inc. - Common Stock (TARA) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,357,920 shares.
The largest 10 holders included
Opaleye Management Inc., VANGUARD GROUP INC, Boxer Capital, LLC, BAKER BROS. ADVISORS LP, Ikarian Capital, LLC, Privium Fund Management (UK) Ltd, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, and CITADEL ADVISORS LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.